Coverage
-
April 25, 2017
Merck Sharp & Dohme Corp. and PDL BioPharma Inc. have called a truce in a patent infringement dispute over Merck's cancer drug Keytruda, as the companies announced Monday that Merck will pay $19.5 million to license related patent rights and dismiss the case.
1 other articles on this case.
View all »